RANI

Rani Therapeutics Holdings Inc

0.5518

Nov 02 • 3:59 PM ET -0.0382 (-6.47%)

0.5518

Aftermarket • 4:15 PM ET 0.0000 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: ORMP ENTX VANI LPCN HALO PYPD VKTX NTRB AQST NVO

| Held by: VTI VXF IBBQ BIB

Scroll to Statements

Index	-
Market Cap	76.92M
Enterprise Value	35.63M
Income	-30.14M
Sales	4.88M
Book/sh	0.35
Cash/sh	0.38
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	71
IPO	Jul 30, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	15.76
P/B	1.58
P/C	1.44
P/FCF	-
EV/EBITDA	-
EV/Sales	7.30
Quick Ratio	5.31
Current Ratio	5.31
Debt/Eq	0.09
LT Debt/Eq	0.06
Option/Short	Yes / Yes

EPS (ttm)	-0.27
EPS next Y	-0.19
EPS next Q	-0.05
EPS this Y	61.11%
EPS next Y	-8.57%
EPS next 5Y	28.43%
EPS past 3/5Y	29.57% 11.92%
Sales past 3/5Y	- 28.73%
EPS Y/Y TTM	70.84%
Sales Y/Y TTM	306.42%
EPS Q/Q	78.43%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	20.00% 84.49%

Insider Own	23.76%
Insider Trans	0.19%
Inst Own	28.76%
Inst Trans	3.12%
ROA	-77.54%
ROE	-179.10%
ROIC	-72.71%
Gross Margin	84.21%
Oper. Margin	-675.78%
Profit Margin	-618.04%
SMA20	-17.63%
SMA50	-27.57%
SMA200	-40.58%
Trades

Shs Outstand	112.50M
Shs Float	88.00M
Short Float	9.27%
Short Ratio	13.75
Short Interest	8.16M
52W High	2.63 -79.02%
52W Low	0.57 -3.77%
Volatility	4.95% 6.51%
ATR (14)	0.04
RSI (14)	27.41
Beta	0.63
Rel Volume	0.69
Avg Volume	593.45K
Volume	412,246

Perf Week	-10.60%
Perf Month	-31.94%
Perf Quarter	-32.71%
Perf Half Y	-40.81%
Perf YTD	-59.13%
Perf Year	-74.92%
Perf 3Y	-70.96%
Perf 5Y	-97.90%
Perf 10Y	-
Recom	1.00
Target Price	7.20
Prev Close	0.59
Price	0.55
Change %	-6.47%

Consensus

Strong Buy

Avg. Price Target

$7.20

Implied Upside

+1,204.8%

Analysts9incl. previous ratings

Rating Distribution9 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 18, 2026	Initiated	CChardan Capital Markets	Buy	$6	+987.4%
Apr 14, 2026	Initiated	LLake Street	Buy	$9	+1,531.0%
Aug 02, 2024	Initiated	OOppenheimer	Outperform	$17	+2,980.8%
Jun 14, 2024	Initiated	MMaxim Group	Buy	$15	+2,618.4%
Jun 13, 2024	Initiated	RRodman & Renshaw	Buy	$10	+1,712.3%
Apr 17, 2023	Resumed	BBTIG Research	Buy	$24	+4,249.4%
Oct 11, 2022	Initiated	UUBS	Buy	$15	+2,618.4%
Jul 27, 2022	Initiated	HH.C. Wainwright	Buy	$22	+3,887.0%
Jun 13, 2022	Initiated	WWedbush	Outperform	$28	+4,974.3%

Oct-13-26 04:05PM	Rani Therapeutics to Participate in the Chardan Healthcare Conference (GlobeNewswire) -8.59%
Oct-05-26 08:00AM	Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP) (GlobeNewswire)
Sep-08-26 08:00AM	Rani Therapeutics to Participate in Upcoming September Conferences (GlobeNewswire)
Aug-13-26 04:05PM	Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update (GlobeNewswire)
Aug-10-26 08:00AM	Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference (GlobeNewswire)
08:00AM	Loading…
Aug-04-26 08:00AM	Rani Therapeutics Appoints Michelle Gilson to Board of Directors (GlobeNewswire)
Jul-20-26 04:05PM	Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-15-26 08:00AM	Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing (GlobeNewswire)
Jul-09-26 04:05PM	Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates (GlobeNewswire)
Jun-29-26 08:00AM	Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer (GlobeNewswire)
May-26-26 08:00AM	Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -12.10%
May-15-26 04:05PM	Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition (GlobeNewswire) -9.97%
May-12-26 04:05PM	Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference (GlobeNewswire)
Apr-09-26 07:00AM	Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy (GlobeNewswire) -6.15%
Mar-26-26 04:05PM	Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update (GlobeNewswire) -5.26% -24.94%
04:53PM	Loading…
Mar-25-26 04:53PM	Rani Therapeutics Appoints Jesper Hoiland as Head of Strategy to Advance Corporate and Pipeline Prioritization (GlobeNewswire) +7.55%
09:19AM	What To Expect From Rani Therapeutics Holdings Inc (RANI) Q4 2025 Earnings (GuruFocus.com)
Mar-19-26 04:05PM	Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Jan-28-26 07:00AM	Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer (GlobeNewswire)
Jan-24-26 08:45AM	Largest borrow rate increases among liquid names (TipRanks)
Jan-08-26 07:00AM	Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill for the Treatment of Obesity in Collaboration with ProGen (GlobeNewswire)
Nov-24-25 04:05PM	Rani Therapeutics to Participate in the Evercore Healthcare Conference (GlobeNewswire)
Nov-06-25 04:30PM	Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update (GlobeNewswire) -9.20% -11.01%
Oct-30-25 08:00AM	Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill Capsule at ObesityWeek 2025 (GlobeNewswire) -12.65%
Oct-26-25 06:05AM	H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill Potential (Insider Monkey)
Oct-23-25 04:05PM	Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors (GlobeNewswire) -13.46% -12.92%
04:01PM	Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules (GlobeNewswire)
Oct-17-25 01:12PM	Why Rani Therapeutics (RANI) Stock Is Soaring Friday? (GuruFocus.com) +248.27%
07:31AM	Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules (GlobeNewswire)
07:30AM	Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing (GlobeNewswire)
04:05PM	Loading…
Aug-07-25 04:05PM	Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update (GlobeNewswire)
Jul-15-25 09:00AM	Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering (GlobeNewswire) -38.92%
Jul-14-25 05:00AM	Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery (GlobeNewswire) +8.45%
May-19-25 08:00AM	Rani Therapeutics Announces Research Agreement with Chugai (GlobeNewswire) +9.27%
May-13-25 04:05PM	Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update (GlobeNewswire) -21.42% +15.59%
Apr-01-25 10:55AM	Q4 2024 Rani Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
03:05AM	Rani Therapeutics Holdings Inc (RANI) Q4 2024 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com)
Mar-31-25 07:15PM	Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript (Seeking Alpha) -7.35%
04:05PM	Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update (GlobeNewswire)
Mar-26-25 04:05PM	Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill Capsule, to Subcutaneously Administered PG-102 (GlobeNewswire) -6.29%
Mar-25-25 06:00PM	Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-05-25 04:05PM	Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill HC (GlobeNewswire) +5.11% +14.58%
Nov-14-24 08:00AM	Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update (GlobeNewswire)
Nov-07-24 04:05PM	Rani Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-17-24 08:00AM	Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist (GlobeNewswire)
Oct-15-24 08:30AM	Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants (GlobeNewswire) -33.33%
Oct-13-24 06:01AM	Oppenheimer Predicts up to 740% Rally for These 2 Strong Buy Stocks (TipRanks)
Oct-08-24 04:05PM	Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire) +7.31%
Sep-03-24 04:05PM	Rani Therapeutics to Participate in September Investor Conferences (GlobeNewswire) -7.50%
Aug-06-24 04:05PM	Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update (GlobeNewswire)
Jul-29-24 04:05PM	Rani Therapeutics to Participate in August Investor Conferences (GlobeNewswire)
Jul-22-24 08:30AM	Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering (GlobeNewswire)
Jun-24-24 07:00AM	Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment (GlobeNewswire)
May-16-24 10:15AM	UBS Adjusts Rani Therapeutics Price Target to $8 From $4, Maintains Buy Rating (MT Newswires)
May-14-24 08:00AM	Rani Therapeutics to Participate in May Investor Conferences (GlobeNewswire) -5.40%
May-09-24 08:00AM	Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill Capsule at Digestive Disease Week 2024 (GlobeNewswire) -5.17%
May-07-24 09:06PM	Rani Therapeutics Q1 2024 Earnings: Financial Performance and Strategic Updates (GuruFocus.com)
May-06-24 09:55PM	RANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q1 2024 (InvestorPlace) +5.73%
04:05PM	Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update (GlobeNewswire)
Mar-21-24 09:45AM	Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:35AM	Q4 2023 Rani Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-24 04:05PM	Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update (GlobeNewswire)
Mar-15-24 04:05PM	Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +6.25%
Feb-05-24 08:00AM	Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) (GlobeNewswire) +5.73%
Dec-14-23 08:00AM	Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist (GlobeNewswire)
Dec-07-23 12:00PM	What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy Stock (Zacks)
Nov-08-23 05:53PM	Rani Therapeutics Holdings Inc (RANI) Reports Q3 2023 Financial Results and Corporate Developments (GuruFocus.com)
04:05PM	Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update (GlobeNewswire)
Nov-01-23 04:05PM	Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-25-23 08:00AM	The RaniPill Capsule, Rani Therapeutics' Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study (GlobeNewswire)
Oct-19-23 04:05PM	Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study (GlobeNewswire)
Oct-12-23 04:05PM	Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research (GlobeNewswire)
Sep-18-23 08:00AM	Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43) (GlobeNewswire)
Sep-07-23 04:05PM	Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies (GlobeNewswire)
Sep-06-23 08:00AM	Rani Therapeutics to Participate in September Investor Conferences (GlobeNewswire)
Aug-11-23 04:05PM	Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update (GlobeNewswire)
Aug-04-23 04:05PM	Rani Therapeutics to Participate in August Investor Conferences (GlobeNewswire)
Jun-21-23 08:00AM	Rani Therapeutics Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference (GlobeNewswire)
Jun-08-23 08:00AM	Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference (GlobeNewswire)
Jun-05-23 08:00AM	Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105 (GlobeNewswire)
Jun-01-23 08:00AM	Rani Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-31-23 08:00AM	Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference (GlobeNewswire)
May-24-23 08:00AM	Rani Therapeutics Appoints Kate McKinley as Chief Business Officer (GlobeNewswire)
May-17-23 09:50AM	2 Strong Buy Penny Stocks With Over 400% Upside on the Horizon (TipRanks) +12.25%
May-10-23 04:05PM	Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update (GlobeNewswire) -8.84%
Apr-26-23 06:46AM	Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) last week's 14% decline must have disappointed private companies who have a significant stake (Simply Wall St.)
Apr-25-23 08:00AM	Rani Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ (GlobeNewswire)
Apr-11-23 08:00AM	Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-23 07:12AM	Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-22-23 04:05PM	Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update (GlobeNewswire) -6.89%
Mar-16-23 04:05PM	Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates (GlobeNewswire) +5.71%
Jan-09-23 08:30AM	Celltrion and Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment (GlobeNewswire)
Jan-05-23 04:05PM	Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update (GlobeNewswire) +8.12%
Dec-06-22 04:05PM	Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study (GlobeNewswire) +9.67%
Nov-17-22 05:30AM	Private companies among Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders, saw gain in holdings value after stock jumped 21% last week (Simply Wall St.)
Nov-10-22 05:25PM	Rani Therapeutics Holdings, Inc. (RANI) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Rani Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-09-22 04:05PM	Rani Therapeutics to Present at the Stifel Healthcare Conference (GlobeNewswire)
Oct-28-22 09:55AM	Here's Why Rani Therapeutics Holdings, Inc. (RANI) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Oct-24-22 08:30AM	Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update (GlobeNewswire) -10.03%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
IMRAN MIR A	Director	Jul 21 '26	Buy	0.69	36,000	24,840	2,119,334	Jul 23 04:10 PM
Javadi Alireza	Chief Technical Officer	Mar 27 '26	Sale	0.78	386	301	9,689	Jul 21 07:24 PM
Imran Talat	Chief Executive Officer	Jul 17 '26	Buy	0.72	35,000	25,193	469,736	Jul 21 06:29 PM

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

Executive ChairmanMr. Mir A. Imran

CEO & DirectorMr. Talat Imran

Chief Business OfficerMs. Kate McKinley M.B.A.

Chief Financial OfficerMr. Nicholas Maestas

Chief Technical OfficerMr. Alireza Javadi Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RANI

Rani Therapeutics Holdings Inc

Upgrade your Finviz experience